Company intelligence / Profile preview

Mayfield Pharmaceuticals

USA

Ownership: Private
Development stage: Other

Overview

Mayfield Pharmaceuticals is focused on developing branded small molecule therapeutics targeting major unmet needs in women’s health, with its most advanced assets in preclinical or pre-IND planning. Lead programs address bacterial vaginosis (MAY-66; first-in-class), dyspareunia (MAY-44; topical non-estrogen), and moderate to severe interstitial cystitis (MAY-88; patent-pending oral suspension). Early data are reported as promising; clinical trials have not yet commenced as of latest public update.

Therapeutic areas: NephrologyWomen's Health
Modalities: Small molecule
Industry: Biotech

Drug pipeline

3 assets

MAY-88

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Harrow Health

Beyond the preview

Go deeper on Mayfield Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mayfield Pharmaceuticals.

Explore the full profile